Neuroblastoma
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ries, 1999, 99
Stiller, 1992, International variations in the incidence of neuroblastoma, Int J Cancer, 52, 538, 10.1002/ijc.2910520407
Heck, 2009, The epidemiology of neuroblastoma: a review, Paediatr Perinat Epidemiol, 23, 125, 10.1111/j.1365-3016.2008.00983.x
Spix, 2006, Neuroblastoma incidence and survival in European children (1978–1997): report from the automated childhood cancer information system project, Eur J Cancer, 42, 2081, 10.1016/j.ejca.2006.05.008
London, 2005, Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group, J Clin Oncol, 23, 6459, 10.1200/JCO.2005.05.571
Johnson, 2011, Survival by race among children with extracranial solid tumors in the United States between 1985 and 2005, Pediatr Blood Cancer, 56, 425, 10.1002/pbc.22825
Henderson, 2011, Racial and ethnic disparities in risk and survival in children with neuroblastoma: a Children's Oncology Group study, J Clin Oncol, 29, 76, 10.1200/JCO.2010.29.6103
Pinto, 2014, Treatment of two cases with refractory, metastatic intermediate-risk neuroblastoma with isotretinoin alone or observation, Pediatr Blood Cancer, 61, 1104, 10.1002/pbc.24889
Zahm, 1995, Childhood cancer: overview of incidence trends and environmental carcinogens, Environ Health Perspect, 103, 177, 10.1289/ehp.95103s6177
Connelly, 2007, Environmental risk factors for brain tumors, Curr Neurol Neurosci Rep, 7, 208, 10.1007/s11910-007-0032-4
Yamamoto, 1995, Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan, J Clin Oncol, 13, 2033, 10.1200/JCO.1995.13.8.2033
Yamamoto, 2002, Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: cohort study in seven prefectures in Japan, J Clin Oncol, 20, 1209, 10.1200/JCO.20.5.1209
Hiyama, 2008, Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study, Lancet, 371, 1173, 10.1016/S0140-6736(08)60523-1
Schilling, 2002, Neuroblastoma screening at one year of age, N Engl J Med, 346, 1047, 10.1056/NEJMoa012277
Woods, 2002, Screening of infants and mortality due to neuroblastoma, N Engl J Med, 346, 1041, 10.1056/NEJMoa012387
Maris, 2008, Screening for neuroblastoma: a resurrected idea?, Lancet, 371, 1142, 10.1016/S0140-6736(08)60500-0
Shojaei-Brosseau, 2004, Genetic epidemiology of neuroblastoma: a study of 426 cases at the Institut Gustave-Roussy in France, Pediatr Blood Cancer, 42, 99, 10.1002/pbc.10381
Trochet, 2004, Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma, Am J Hum Genet, 74, 761, 10.1086/383253
Rohrer, 2002, Congenital central hypoventilation syndrome associated with Hirschsprung's disease and neuroblastoma: case of multiple neurocristopathies, Pediatr Pulmonol, 33, 71, 10.1002/ppul.10031
Mosse, 2004, Germline PHOX2B mutation in hereditary neuroblastoma, Am J Hum Genet, 75, 727, 10.1086/424530
Brems, 2009, Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1, Lancet Oncol, 10, 508, 10.1016/S1470-2045(09)70033-6
Clausen, 1989, Familial occurrence of neuroblastoma, von Recklinghausen's neurofibromatosis, Hirschsprung's agangliosis and jaw-winking syndrome, Acta Paediatr Scand, 78, 736, 10.1111/j.1651-2227.1989.tb11135.x
Longo, 2007, Genetic predisposition to familial neuroblastoma: identification of two novel genomic regions at 2p and 12p, Hum Hered, 63, 205, 10.1159/000099997
Tonini, 2001, Exclusion of candidate genes and chromosomal regions in familial neuroblastoma, Int J Mol Med, 7, 85
Maris, 1996, Familial predisposition to neuroblastoma does not map to chromosome band 1p36, Cancer Res, 56, 3421
Maris, 2002, Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13, Cancer Res, 62, 6651
Mosse, 2008, Identification of ALK as a major familial neuroblastoma predisposition gene, Nature, 455, 930, 10.1038/nature07261
Janoueix-Lerosey, 2008, Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma, Nature, 455, 967, 10.1038/nature07398
de Pontual, 2011, Germline gain-of-function mutations of ALK disrupt central nervous system development, Hum Mutat, 32, 272, 10.1002/humu.21442
George, 2008, Activating mutations in ALK provide a therapeutic target in neuroblastoma, Nature, 455, 975, 10.1038/nature07397
Chen, 2008, Oncogenic mutations of ALK kinase in neuroblastoma, Nature, 455, 971, 10.1038/nature07399
Schulte, 2011, High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma, Clin Cancer Res, 17, 5082, 10.1158/1078-0432.CCR-10-2809
Weiser, 2011, Stratification of patients with neuroblastoma for targeted ALK inhibitor therapy, J Clin Oncol, 29, 10.1200/jco.2011.29.15_suppl.9514
Berry, 2012, The ALK (F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma, Cancer Cell, 22, 117, 10.1016/j.ccr.2012.06.001
Heukamp, 2012, Targeted expression of mutated ALK induces neuroblastoma in transgenic mice, Sci Transl Med, 4, 141ra191, 10.1126/scitranslmed.3003967
Zhu, 2012, Activated ALK collaborates with MYCN in neuroblastoma pathogenesis, Cancer Cell, 21, 362, 10.1016/j.ccr.2012.02.010
Mosse, 2013, Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a children's oncology group phase 1 consortium study, Lancet Oncol, 14, 472, 10.1016/S1470-2045(13)70095-0
DeBaun, 1998, Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry, J Pediatr, 132, 398, 10.1016/S0022-3476(98)70008-3
Birch, 2001, Relative frequency and morphology of cancers in carriers of germline TP53 mutations, Oncogene, 20, 4621, 10.1038/sj.onc.1204621
Rossbach, 2008, Composite adrenal anaplastic neuroblastoma and virilizing adrenocortical tumor with germline TP53 R248W mutation, Pediatr Blood Cancer, 50, 681, 10.1002/pbc.21219
Bissig, 2002, Co-occurrence of neuroblastoma and nephroblastoma in an infant with Fanconi's anemia, Hum Pathol, 33, 1047, 10.1053/hupa.2002.128062
Reid, 2007, Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer, Nat Genet, 39, 162, 10.1038/ng1947
Maris, 2008, Chromosome 6p22 locus associated with clinically aggressive neuroblastoma, N Engl J Med, 358, 2585, 10.1056/NEJMoa0708698
Diskin, 2012, Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma, Nat Genet, 44, 1126, 10.1038/ng.2387
Capasso, 2009, Common variations in BARD1 influence susceptibility to high-risk neuroblastoma, Nat Genet, 41, 718, 10.1038/ng.374
Diskin, 2009, Copy number variation at 1q21.1 associated with neuroblastoma, Nature, 459, 987, 10.1038/nature08035
Wang, 2011, Integrative genomics identifies LMO1 as a neuroblastoma oncogene, Nature, 469, 216, 10.1038/nature09609
Diskin, 2014, Rare variants in TP53 and susceptibility to neuroblastoma, J Natl Cancer Inst, 106, dju047, 10.1093/jnci/dju047
Vo, 2014, Clinical, biological and prognostic differences based on primary tumor site in neuroblastoma: a report from the International Neuroblastoma Risk Group (INRG) project, J Clin Oncol, 32, 3169, 10.1200/JCO.2014.56.1621
De Bernardi, 2001, Neuroblastoma with symptomatic spinal cord compression at diagnosis: treatment and results with 76 cases, J Clin Oncol, 19, 183, 10.1200/JCO.2001.19.1.183
El Shafie, 1983, Intractable diarrhea in children with VIP-secreting ganglioneuroblastomas, J Pediatr Surg, 18, 34, 10.1016/S0022-3468(83)80269-3
Scheibel, 1982, Vasoactive intestinal polypeptide (VIP) in children with neural crest tumours, Acta Paediatr Scand, 71, 721, 10.1111/j.1651-2227.1982.tb09510.x
Matthay, 2005, Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004, Cancer Lett, 228, 275, 10.1016/j.canlet.2005.01.051
Gorman, 2010, Update on diagnosis, treatment, and prognosis in opsoclonus-myoclonus-ataxia syndrome, Curr Opin Pediatr, 22, 745, 10.1097/MOP.0b013e32833fde3f
Dubois, 2008, Lung metastases in neuroblastoma at initial diagnosis: a report from the International Neuroblastoma Risk Group (INRG) project, Pediatr Blood Cancer, 51, 589, 10.1002/pbc.21684
Kramer, 2001, Neuroblastoma metastatic to the central nervous system. The Memorial Sloan-Kettering Cancer Center experience and a literature review, Cancer, 91, 1510, 10.1002/1097-0142(20010415)91:8<1510::AID-CNCR1159>3.0.CO;2-I
Matthay, 2003, Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients, Cancer, 98, 155, 10.1002/cncr.11448
Evans, 1980, A review of 17 IV-S neuroblastoma patients at the Children's Hospital of Philadelphia, Cancer, 45, 833, 10.1002/1097-0142(19800301)45:5<833::AID-CNCR2820450502>3.0.CO;2-U
Simon, 2008, Review of image defined risk factors in localized neuroblastoma patients: results of the GPOH NB97 trial, Pediatr Blood Cancer, 50, 965, 10.1002/pbc.21343
Cecchetto, 2005, Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group, J Clin Oncol, 23, 8483, 10.1200/JCO.2005.02.4661
Messina, 2006, Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma, Pediatr Blood Cancer, 47, 865, 10.1002/pbc.20777
Yanik, 2013, Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the children's oncology group, J Nucl Med, 54, 541, 10.2967/jnumed.112.112334
Park, 2013, Children's Oncology Group's 2013 blueprint for research: neuroblastoma, Pediatr Blood Cancer, 60, 985, 10.1002/pbc.24433
Sharp, 2009, 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma, J Nucl Med, 50, 1237, 10.2967/jnumed.108.060467
Zhang, 2014, Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG, Clin Cancer Res, 20, 2182, 10.1158/1078-0432.CCR-13-1153
Taggart, 2009, Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma, J Clin Oncol, 27, 5343, 10.1200/JCO.2008.20.5732
Brodeur, 1993, Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment, J Clin Oncol, 11, 1466, 10.1200/JCO.1993.11.8.1466
Brodeur, 1988, International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma, J Clin Oncol, 6, 1874, 10.1200/JCO.1988.6.12.1874
Cohn, 2009, The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report, J Clin Oncol, 27, 289, 10.1200/JCO.2008.16.6785
Monclair, 2009, The International Neuroblastoma Risk Group (INRG) staging system: an INRG task force report, J Clin Oncol, 27, 298, 10.1200/JCO.2008.16.6876
Morgenstern, 2014, Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: a study from the International Neuroblastoma Risk Group Database, J Clin Oncol, 32, 1228, 10.1200/JCO.2013.53.6342
Hartmann, 1999, Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution, Bone Marrow Transplant, 23, 789, 10.1038/sj.bmt.1701737
George, 2005, Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a pediatric oncology group study, J Clin Oncol, 23, 6466, 10.1200/JCO.2005.05.582
Schmidt, 2005, Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group study, J Clin Oncol, 23, 6474, 10.1200/JCO.2005.05.183
Park, 2009, Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the children's oncology group, Pediatr Blood Cancer, 52, 44, 10.1002/pbc.21784
Park, 2010, Neuroblastoma: biology, prognosis, and treatment, Hematol Oncol Clin North Am, 24, 65, 10.1016/j.hoc.2009.11.011
Mosse, 2014, Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project, Pediatr Blood Cancer, 61, 627, 10.1002/pbc.24777
Shimada, 1984, Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas, J Natl Cancer Inst, 73, 405, 10.1093/jnci/73.2.405
Shimada, 1995, Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis, J Natl Cancer Inst, 87, 1470, 10.1093/jnci/87.19.1470
Shimada, 1999, The International Neuroblastoma Pathology Classification (the Shimada system), Cancer, 86, 364, 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.0.CO;2-7
Strother, 2012, Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of children's oncology group study P9641, J Clin Oncol, 30, 1842, 10.1200/JCO.2011.37.9990
Ambros, 2009, International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee, Br J Cancer, 100, 1471, 10.1038/sj.bjc.6605014
Seeger, 1985, Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas, N Engl J Med, 313, 1111, 10.1056/NEJM198510313131802
Brodeur, 1984, Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage, Science, 224, 1121, 10.1126/science.6719137
Huang, 2013, Neuroblastoma and MYCN, Cold Spring Harb Perspect Med, 3, a014415, 10.1101/cshperspect.a014415
Cohn, 1995, Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study, Cancer Res, 55, 721
Bagatell, 2009, Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database, J Clin Oncol, 27, 365, 10.1200/JCO.2008.17.9184
Weiss, 1997, Targeted expression of MYCN causes neuroblastoma in transgenic mice, EMBO J, 16, 2985, 10.1093/emboj/16.11.2985
Puissant, 2013, Targeting MYCN in neuroblastoma by BET bromodomain inhibition, Cancer Discov, 3, 308, 10.1158/2159-8290.CD-12-0418
Carpenter, 2012, Targeting ALK in neuroblastoma–preclinical and clinical advancements, Nat Rev Clin Oncol, 9, 391, 10.1038/nrclinonc.2012.72
Bown, 1999, Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma, N Engl J Med, 340, 1954, 10.1056/NEJM199906243402504
Meddeb, 1996, Additional copies of a 25 Mb chromosomal region originating from 17q23.1-17qter are present in 90% of high-grade neuroblastomas, Genes Chromosomes Cancer, 17, 156, 10.1002/(SICI)1098-2264(199611)17:3<156::AID-GCC3>3.0.CO;2-3
Attiyeh, 2005, Chromosome 1p and 11q deletions and outcome in neuroblastoma, N Engl J Med, 353, 2243, 10.1056/NEJMoa052399
Caron, 1996, Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma, N Engl J Med, 334, 225, 10.1056/NEJM199601253340404
Riley, 2004, A systematic review of molecular and biological tumor markers in neuroblastoma, Clin Cancer Res, 10, 4, 10.1158/1078-0432.CCR-1051-2
Fujita, 2008, CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas, J Natl Cancer Inst, 100, 940, 10.1093/jnci/djn176
Liu, 2011, CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression, Cell Death Differ, 18, 1174, 10.1038/cdd.2010.187
Guo, 1999, Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas, Oncogene, 18, 4948, 10.1038/sj.onc.1202887
Nowacki, 2008, Expression of the tumour suppressor gene CADM1 is associated with favourable outcome and inhibits cell survival in neuroblastoma, Oncogene, 27, 3329, 10.1038/sj.onc.1210996
Janoueix-Lerosey, 2009, Overall genomic pattern is a predictor of outcome in neuroblastoma, J Clin Oncol, 27, 1026, 10.1200/JCO.2008.16.0630
Schleiermacher, 2012, Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project, Br J Cancer, 107, 1418, 10.1038/bjc.2012.375
Schleiermacher, 2007, Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification, Br J Cancer, 97, 238, 10.1038/sj.bjc.6603820
Katzenstein, 1998, Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the Pediatric Oncology Group experience–a pediatric oncology group study, J Clin Oncol, 16, 2007, 10.1200/JCO.1998.16.6.2007
Look, 1991, Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study, J Clin Oncol, 9, 581, 10.1200/JCO.1991.9.4.581
Bowman, 1997, Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study, J Natl Cancer Inst, 89, 373, 10.1093/jnci/89.5.373
Baker, 2010, Outcome after reduced chemotherapy for intermediate-risk neuroblastoma, N Engl J Med, 363, 1313, 10.1056/NEJMoa1001527
Molenaar, 2012, Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes, Nature, 483, 589, 10.1038/nature10910
Sausen, 2013, Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma, Nat Genet, 45, 12, 10.1038/ng.2493
Cheung, 2012, Association of age at diagnosis and genetic mutations in patients with neuroblastoma, JAMA, 307, 1062, 10.1001/jama.2012.228
De Brouwer, 2010, Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification, Clin Cancer Res, 16, 4353, 10.1158/1078-0432.CCR-09-2660
Passoni, 2009, Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients, Cancer Res, 69, 7338, 10.1158/0008-5472.CAN-08-4419
Schleiermacher, 2014, Emergence of new ALK mutations at relapse of neuroblastoma, J Clin Oncol, 32, 2727, 10.1200/JCO.2013.54.0674
Hovestadt, 2014, Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing, Nature, 510, 537, 10.1038/nature13268
Cole, 2012, New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome, Clin Cancer Res, 18, 2423, 10.1158/1078-0432.CCR-11-1409
Cheung, 2013, Neuroblastoma: developmental biology, cancer genomics and immunotherapy, Nat Rev Cancer, 13, 397, 10.1038/nrc3526
Brodeur, 2009, Trk receptor expression and inhibition in neuroblastomas, Clin Cancer Res, 15, 3244, 10.1158/1078-0432.CCR-08-1815
Diede, 2014, Spontaneous regression of metastatic cancer: learning from neuroblastoma, Nat Rev Cancer, 14, 71, 10.1038/nrc3656
Minturn, 2011, Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study, Cancer Chemother Pharmacol, 68, 1057, 10.1007/s00280-011-1581-4
Pastorino, 2009, Recent advances in targeted anti-vasculature therapy: the neuroblastoma model, Curr Drug Targets, 10, 1021, 10.2174/138945009789577954
Barone, 2014, MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance, Curr Drug Targets, 15, 114, 10.2174/13894501113149990194
Goldsmith, 2010, BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists, Cell Death Differ, 17, 872, 10.1038/cdd.2009.171
Henderson, 2011, ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux, J Natl Cancer Inst, 103, 1236, 10.1093/jnci/djr256
Teitz, 2000, Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN, Nat Med, 6, 529, 10.1038/75007
Yang, 2004, Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma, Clin Cancer Res, 10, 8493, 10.1158/1078-0432.CCR-04-1331
Astuti, 2001, RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours, Oncogene, 20, 7573, 10.1038/sj.onc.1204968
George, 2010, Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a children's oncology group study, Pediatr Blood Cancer, 55, 629, 10.1002/pbc.22607
Rossler, 2008, Angiogenesis as a target in neuroblastoma, Eur J Cancer, 44, 1645, 10.1016/j.ejca.2008.05.015
Glade Bender, 2011, Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors, Oncologist, 16, 1614, 10.1634/theoncologist.2011-0148
Glade Bender, 2012, A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report, Clin Cancer Res, 18, 5081, 10.1158/1078-0432.CCR-12-0078
Vermeulen, 2009, Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study, Lancet Oncol, 10, 663, 10.1016/S1470-2045(09)70154-8
De Preter, 2010, Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature, Clin Cancer Res, 16, 1532, 10.1158/1078-0432.CCR-09-2607
Oberthuer, 2006, Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification, J Clin Oncol, 24, 5070, 10.1200/JCO.2006.06.1879
Oberthuer, 2010, Prognostic impact of gene expression-based classification for neuroblastoma, J Clin Oncol, 28, 3506, 10.1200/JCO.2009.27.3367
Garcia, 2012, A three-gene expression signature model for risk stratification of patients with neuroblastoma, Clin Cancer Res, 18, 2012, 10.1158/1078-0432.CCR-11-2483
Stricker, 2014, Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter system, Mol Oncol, 8, 669, 10.1016/j.molonc.2014.01.010
Asgharzadeh, 2006, Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification, J Natl Cancer Inst, 98, 1193, 10.1093/jnci/djj330
Asgharzadeh, 2012, Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma, J Clin Oncol, 30, 3525, 10.1200/JCO.2011.40.9169
Buckley, 2010, Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- neuroblastoma, Clin Cancer Res, 16, 2971, 10.1158/1078-0432.CCR-09-3215
Chen, 2007, Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis, Cancer Res, 67, 976, 10.1158/0008-5472.CAN-06-3667
De Preter, 2011, miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples, Clin Cancer Res, 17, 7684, 10.1158/1078-0432.CCR-11-0610
Buechner, 2012, N-myc and noncoding RNAs in neuroblastoma, Mol Cancer Res, 10, 1243, 10.1158/1541-7786.MCR-12-0244
Alvarado, 2000, Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group study, J Pediatr Hematol Oncol, 22, 197, 10.1097/00043426-200005000-00003
Perez, 2000, Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a Children's Cancer Group study, J Clin Oncol, 18, 18, 10.1200/JCO.2000.18.1.18
Simon, 2004, New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status, J Pediatr Hematol Oncol, 26, 791
Simon, 2006, Risk estimation in localized unresectable single copy MYCN neuroblastoma by the status of chromosomes 1p and 11q, Cancer Lett, 237, 215, 10.1016/j.canlet.2005.06.001
Yamamoto, 1998, Spontaneous regression of localized neuroblastoma detected by mass screening, J Clin Oncol, 16, 1265, 10.1200/JCO.1998.16.4.1265
Woods, 1996, A population-based study of the usefulness of screening for neuroblastoma, Lancet, 348, 1682, 10.1016/S0140-6736(96)06020-5
Oue, 2005, Profile of neuroblastoma detected by mass screening, resected after observation without treatment: results of the wait and see pilot study, J Pediatr Surg, 40, 359, 10.1016/j.jpedsurg.2004.10.062
Rubie, 2011, Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1, J Clin Oncol, 29, 449, 10.1200/JCO.2010.29.5196
Hero, 2008, Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97, J Clin Oncol, 26, 1504, 10.1200/JCO.2007.12.3349
Nuchtern, 2012, A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a children's oncology group study, Ann Surg, 256, 573, 10.1097/SLA.0b013e31826cbbbd
D'Angio, 1971, Special pattern of widespread neuroblastoma with a favourable prognosis, Lancet, 1, 1046, 10.1016/S0140-6736(71)91606-0
Nickerson, 2000, Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study, J Clin Oncol, 18, 477, 10.1200/JCO.2000.18.3.477
Twist, 2014, Maintaining outstanding outcomes using response- and biology-based therapy for intermediate-risk neuroblastoma: a report from the Children’s Oncology Group study ANBL0531, J Clin Oncol, 32, 5s, 10.1200/jco.2014.32.15_suppl.10006
De Bernardi, 2008, Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group, Br J Cancer, 99, 1027, 10.1038/sj.bjc.6604640
Matthay, 1998, Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study, J Clin Oncol, 16, 1256, 10.1200/JCO.1998.16.4.1256
Schmidt, 2000, Biologic factors determine prognosis in infants with stage IV neuroblastoma: a prospective Children's Cancer Group study, J Clin Oncol, 18, 1260, 10.1200/JCO.2000.18.6.1260
Meany, 2014, Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group Project, Pediatr Blood Cancer, 61, 1932, 10.1002/pbc.25134
Kushner, 1996, Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy, J Clin Oncol, 14, 373, 10.1200/JCO.1996.14.2.373
Ladernstein, 2011, Busulfan-melphalan as a myeloablative therapy (MAT) for high risk neuroblastoma: results from the HR-NBL1/SIOPEN trial. ASCO Annual Meeting Proceedings, J Clin Oncol, 29
Matthay, 2009, Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children's Oncology Group study, J Clin Oncol, 27, 1007, 10.1200/JCO.2007.13.8925
Pearson, 2008, High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial, Lancet Oncol, 9, 247, 10.1016/S1470-2045(08)70069-X
Yu, 2010, Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma, N Engl J Med, 363, 1324, 10.1056/NEJMoa0911123
Berthold, 2005, Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial, Lancet Oncol, 6, 649, 10.1016/S1470-2045(05)70291-6
Kreissman, 2013, Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial, Lancet Oncol, 14, 999, 10.1016/S1470-2045(13)70309-7
Matthay, 1999, Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group, N Engl J Med, 341, 1165, 10.1056/NEJM199910143411601
London, 2010, Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study, J Clin Oncol, 28, 3808, 10.1200/JCO.2009.27.5016
Park, 2011, Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study, J Clin Oncol, 29, 4351, 10.1200/JCO.2010.34.3293
Adkins, 2004, Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study, J Pediatr Surg, 39, 931, 10.1016/j.jpedsurg.2004.02.041
Zwaveling, 2012, Is complete surgical resection of stage 4 neuroblastoma a prerequisite for optimal survival or may >95 % tumour resection suffice?, Pediatr Surg Int, 28, 953, 10.1007/s00383-012-3109-3
Simon, 2013, Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis, J Clin Oncol, 31, 752, 10.1200/JCO.2012.45.9339
Holmes K, ASarnacki S, Poetschger U, et al. Influence of surgical excision on survival of patients with high risk neuroblastoma: report from Study 1 of SIOPEN. Advances in Neuroblastoma Research Meeting, May 15, 2014. Cologne, 2014; PL-012.
Von Allmen D, Davidoff A, London WB, et al. Influence of extent of resection on survival in high risk neuroblasotma: report from COG A3793 Study. Advances in Neuroblastoma Research Meeting, May 15, 2014. Cologne, 2014. 2014; OR-067.
Haas-Kogan, 2003, Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study, Int J Radiat Oncol Biol Phys, 56, 28, 10.1016/S0360-3016(02)04506-6
Kushner, 2001, Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery, J Clin Oncol, 19, 2821, 10.1200/JCO.2001.19.11.2821
Polishchuk, 2014, Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma, Int J Radiat Oncol Biol Phys, 89, 839, 10.1016/j.ijrobp.2014.04.004
Ladenstein, 2008, 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures, Bone Marrow Transplant, 41, S118, 10.1038/bmt.2008.69
Pritchard, 2005, High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group, Pediatr Blood Cancer, 44, 348, 10.1002/pbc.20219
Yalcin, 2013, High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma, Cochrane Database Syst Rev, 10.1002/14651858.CD006301.pub3
George, 2006, High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update, J Clin Oncol, 24, 2891, 10.1200/JCO.2006.05.6986
Simon, 2011, Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy, BMC Cancer, 11, 21, 10.1186/1471-2407-11-21
Cheung, 2012, Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission, J Clin Oncol, 30, 3264, 10.1200/JCO.2011.41.3807
Cohen, 2014, Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: high incidence of endocrine and growth problems, Bone Marrow Transplant, 49, 502, 10.1038/bmt.2013.218
Laverdiere, 2009, Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study, J Natl Cancer Inst, 101, 1131, 10.1093/jnci/djp230
Moreno, 2013, Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experience, Pediatr Blood Cancer, 60, 1135, 10.1002/pbc.24452
Perwein, 2011, Survival and late effects in children with stage 4 neuroblastoma, Pediatr Blood Cancer, 57, 629, 10.1002/pbc.23036
Trahair, 2007, Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation, Bone Marrow Transplant, 40, 741, 10.1038/sj.bmt.1705809
Ross, 2009, Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy, Nat Genet, 41, 1345, 10.1038/ng.478
Martin, 2014, Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma, Pediatr Blood Cancer, 61, 1350, 10.1002/pbc.25033
Kushner, 2009, Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma, Pediatr Blood Cancer, 53, 17, 10.1002/pbc.21931
De Bernardi, 2014, Neuroblastoma with symptomatic epidural compression in the infant: the AIEOP experience, Pediatr Blood Cancer, 61, 1369, 10.1002/pbc.25028
London, 2011, Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project, J Clin Oncol, 29, 3286, 10.1200/JCO.2010.34.3392
Morgenstern, 2013, Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy, J Pediatr Hematol Oncol, 35, 337, 10.1097/MPH.0b013e318299d637
Modak, 2010, Neuroblastoma: therapeutic strategies for a clinical enigma, Cancer Treat Rev, 36, 307, 10.1016/j.ctrv.2010.02.006
Di Giannatale, 2014, Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study, Eur J Cancer, 50, 170, 10.1016/j.ejca.2013.08.012
Kushner, 2010, Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma, Cancer, 116, 3054, 10.1002/cncr.25232
Garaventa, 2003, A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma, Cancer, 98, 2488, 10.1002/cncr.11797
Kushner, 2013, Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature, Cancer, 119, 665, 10.1002/cncr.27783
Lashford, 1992, Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation, J Clin Oncol, 10, 1889, 10.1200/JCO.1992.10.12.1889
Matthay, 2006, Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study, J Clin Oncol, 24, 500, 10.1200/JCO.2005.03.6400
Matthay, 1998, Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma, J Clin Oncol, 16, 229, 10.1200/JCO.1998.16.1.229
Matthay, 2007, Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma, J Clin Oncol, 25, 1054, 10.1200/JCO.2006.09.3484
Xu, 2013, Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFbeta1, Cancer Immunol Immunother, 62, 1637, 10.1007/s00262-013-1466-y
Koehn, 2012, Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma, Front Pharmacol, 3, 91, 10.3389/fphar.2012.00091
Heczey, 2013, Advances in chimeric antigen receptor immunotherapy for neuroblastoma, Discov Med, 16, 287
Louis, 2011, Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma, Blood, 118, 6050, 10.1182/blood-2011-05-354449
Pule, 2008, Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma, Nat Med, 14, 1264, 10.1038/nm.1882
Park, 2007, Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma, Mol Ther, 15, 825, 10.1038/sj.mt.6300104
Bresler, 2011, Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma, Sci Transl Med, 3, 108ra114, 10.1126/scitranslmed.3002950
Barone, 2013, New strategies in neuroblastoma: therapeutic targeting of MYCN and ALK, Clin Cancer Res, 19, 5814, 10.1158/1078-0432.CCR-13-0680
Hogarty, 2008, ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma, Cancer Res, 68, 9735, 10.1158/0008-5472.CAN-07-6866
Witt, 2009, Targeting histone deacetylases in neuroblastoma, Curr Pharm Des, 15, 436, 10.2174/138161209787315774